[1] |
Lu Q, Wu R, Zhao M, et al. miRNAs as therapeutic targets in inflammatory disease[J]. Trends Pharmacol Sci, 2019, 40:853-865.
|
[2] |
Gebert LFR, Macrae IJ. Regulation of microRNA function in animals[J]. Nature Rev Mole Cell Biol, 2019, 20:21-37.
|
[3] |
Zhou H, Hasni Sa, Perez P, et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1[J]. J Am Soc of Nephrol: JASN, 2013, 24:1073-1087.
|
[4] |
Luan J, Fu J, Wang D, et al. In vivo miR-150-Based RNA interference attenuates tubulointerstitial fibrosis through the SOCS1/JAK/STAT Pathway and[J]. Mol Ther Nucleic Acids, 2020, 22:871-884.
|
[5] |
Luan J, Fu J, Chen C, et al. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration[J]. Arthritis Res Ther, 2019, 21:276. doi: 10.1186/s13075-019-2044-2.
|
[6] |
Kong Y, Lu Z, Liu P, et al. Long noncoding RNA: genomics and relevance to physiology[J]. Compr Physiol, 2019, 9:933-946.
|
[7] |
Mukhadi S, Hull R, Mbita Z, et al. The role of micro-RNAs in kidney disease[J]. Non-coding RNA, 2015, 1:192-221.
|
[8] |
Sebastian-Delacruz M, Gonzalez-Moro I, Olazagoitia-Garmendia A, et al. The role of lncRNAs in gene expression regulation through mRNA stabilization[J]. Non-coding RNA, 2021, 7. doi: 10.3390/ncrna7010003.
|
[9] |
Mihaylova G, Vasilev V, Kosturkova Mb, et al. Long non-coding RNAs as new biomarkers in lupus nephritis: a connection between present and future[J]. Cureus, 2020, 12:e9003. doi: 10.7759/cureus.9003.
|
[10] |
Kabekkodu Sp, Shukla V, Varghese Vk, et al. Clustered miRNAs and their role in biological functions and diseases[J]. Biol Rev Camb Philos Soc, 2018, 93:1955-1986.
|
[11] |
Han Y, Ma Z. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis[J]. Anticancer Drugs, 2021, 32:427-436.
|
[12] |
Jiang H, Zhu M, Wang H, et al. Suppression of lncRNA MALAT1 reduces pro-inflammatory cytokines production by regulating miR-150-5p/ZBTB4 axis through JAK/STAT signal pathway in systemic juvenile idiopathic arthritis[J]. Cytokine, 2021, 138:155397. doi: 10.1016/j.cyto.2020.155397.
|
[13] |
Yin Q, He M, Huang L, et al. LncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis[J]. Microvasc Res, 2021, 134:104118. doi: 10.1016/j.mvr.2020.104118.
|
[14] |
Zhao Y, Hong L. LncRNA-PRLB confers paclitaxel resistance of ovarian cancer cells by regulating RSF1/NF-κB signaling pathway[J]. Cancer Biother Radiopharm, 2020, 36:202-210.
|
[15] |
Wang X, Jiang G, Ren W, et al. LncRNA NEAT1 regulates 5-Fu sensitivity, apoptosis and invasion in colorectal cancer through the miR-150-5p/CPSF4 axis[J]. Onco Targets Ther, 2020, 13:6373-6383.
|